[{"id":"e5641ae2-d0c8-4460-9481-ff76fa234ec4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02032810","created_at":"2021-01-18T09:19:16.989Z","updated_at":"2025-02-25T15:41:14.083Z","phase":"Phase 1","brief_title":"Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma","source_id_and_acronym":"NCT02032810","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 01/07/2014","start_date":" 01/07/2014","primary_txt":" Primary completion: 09/06/2017","primary_completion_date":" 09/06/2017","study_txt":" Completion: 09/25/2019","study_completion_date":" 09/25/2019","last_update_posted":"2023-01-20"},{"id":"21f9f5b3-1d3e-4a1a-a254-4ddbfe726e19","acronym":"","url":"https://clinicaltrials.gov/study/NCT01658241","created_at":"2021-01-18T07:09:10.798Z","updated_at":"2024-07-02T16:36:10.820Z","phase":"Phase 2","brief_title":"Panobinostat Biological Correlates Study","source_id_and_acronym":"NCT01658241","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 07/16/2012","start_date":" 07/16/2012","primary_txt":" Primary completion: 03/18/2015","primary_completion_date":" 03/18/2015","study_txt":" Completion: 03/18/2015","study_completion_date":" 03/18/2015","last_update_posted":"2022-05-06"},{"id":"84ed0b0e-8803-431d-ace0-acaa07a9bb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT04804709","created_at":"2021-03-18T11:52:18.385Z","updated_at":"2024-07-02T16:36:17.149Z","phase":"Phase 1","brief_title":"Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)","source_id_and_acronym":"NCT04804709","lead_sponsor":"Cheng-Chia (Fred) Wu","biomarkers":" FUS","pipe":"","alterations":" ","tags":["FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Farydak (panobinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-02-14"},{"id":"202201fa-0c55-460e-bcde-69e99bc6dfa8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00788931","created_at":"2021-01-18T02:59:30.641Z","updated_at":"2024-07-02T16:36:37.112Z","phase":"Phase 1","brief_title":"A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT00788931","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 08/01/2010","primary_completion_date":" 08/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2020-12-19"},{"id":"694aae4f-2bb5-4c6d-9fbf-8b38da8c30f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01013597","created_at":"2021-01-18T03:58:23.715Z","updated_at":"2025-02-25T15:50:36.160Z","phase":"Phase 2","brief_title":"Trial of LBH589 in Metastatic Thyroid Cancer","source_id_and_acronym":"NCT01013597","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" NOTCH1","pipe":" | ","alterations":" NOTCH1 expression","tags":["NOTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOTCH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2019-11-29"},{"id":"6b761ed4-cd67-479d-9291-b441cf39372d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03982134","created_at":"2021-01-18T19:35:17.237Z","updated_at":"2025-02-25T15:43:35.581Z","phase":"Phase 1","brief_title":"PDR001 + Panobinostat for Melanoma and NSCLC","source_id_and_acronym":"NCT03982134","lead_sponsor":"Muhammad Furqan","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK3 • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • ROS1 fusion","tags":["EGFR • BRAF • ALK • ROS1 • NTRK3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • Farydak (panobinostat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2022","study_completion_date":" 05/01/2022","last_update_posted":"2019-10-04"},{"id":"43349add-d0fd-4b29-95e5-140ed45fdea2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01105312","created_at":"2021-01-18T04:22:29.272Z","updated_at":"2024-07-02T16:37:20.600Z","phase":"Phase 1/2","brief_title":"Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01105312","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 09/03/2013","study_completion_date":" 09/03/2013","last_update_posted":"2017-06-27"},{"id":"ac2198c6-82dc-4dc5-9ae4-52b876976d62","acronym":"","url":"https://clinicaltrials.gov/study/NCT01065467","created_at":"2021-01-18T04:11:55.440Z","updated_at":"2025-02-25T15:50:52.615Z","phase":"Phase 1","brief_title":"Panobinostat (LBH589) in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01065467","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MITF","pipe":"","alterations":" ","tags":["MITF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 03/13/2017","study_completion_date":" 03/13/2017","last_update_posted":"2017-03-28"},{"id":"b400aaff-0ff8-4133-ae50-0e48a3aaabc1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00878904","created_at":"2021-01-18T03:21:39.716Z","updated_at":"2024-07-02T16:37:24.123Z","phase":"Phase 1","brief_title":"Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT00878904","lead_sponsor":"University of California, San Francisco","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epirubicin • Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/13/2009","start_date":" 09/13/2009","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 10/10/2016","study_completion_date":" 10/10/2016","last_update_posted":"2017-03-24"},{"id":"38b4ea86-be9b-4593-9561-c706c5419517","acronym":"","url":"https://clinicaltrials.gov/study/NCT00993642","created_at":"2021-01-18T03:52:53.214Z","updated_at":"2025-02-25T15:50:31.130Z","phase":"Phase 1","brief_title":"ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer","source_id_and_acronym":"NCT00993642","lead_sponsor":"Tulane University Health Sciences Center","biomarkers":" ERBB4","pipe":"","alterations":" ","tags":["ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Farydak (panobinostat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 09/01/2010","primary_completion_date":" 09/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2017-03-13"},{"id":"a4c5373e-2003-4db5-8c78-d5c32c973637","acronym":"","url":"https://clinicaltrials.gov/study/NCT00777049","created_at":"2021-01-18T02:56:13.432Z","updated_at":"2024-07-02T16:37:30.548Z","phase":"Phase 2","brief_title":"Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT00777049","lead_sponsor":"Translational Research in Oncology","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Farydak (panobinostat)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2016-07-15"}]